You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer

Article metrics

Article menu

Download PDFPDF

XML
Research Article
A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer

 

Online download statistics by month:

Online download statistics by month: December 2019 to June 2025

AbstractFullPdf
Dec 2019660
Jan 202027272
Feb 202030308
Mar 2020444412
Apr 2020454511
May 2020353514
Jun 202050506
Jul 2020222211
Aug 2020302821
Sep 2020606016
Oct 2020565629
Nov 2020626144
Dec 2020525257
Jan 2021747446
Feb 2021828261
Mar 2021818160
Apr 2021737361
May 2021474735
Jun 2021585833
Jul 2021636343
Aug 2021272714
Sep 2021464636
Oct 2021666656
Nov 2021484846
Dec 2021969741
Jan 2022778125
Feb 202213813928
Mar 2022838938
Apr 202213013132
May 2022586131
Jun 2022818539
Jul 2022808247
Aug 20229110058
Sep 202248849741
Oct 202210811233
Nov 202213613843
Dec 2022697021
Jan 2023777945
Feb 2023767727
Mar 2023828622
Apr 2023828245
May 2023686840
Jun 2023525323
Jul 2023616137
Aug 2023525221
Sep 2023848430
Oct 202316216243
Nov 202325225225
Dec 2023646423
Jan 2024666730
Feb 2024697033
Mar 2024737382
Apr 2024495242
May 202413513541
Jun 2024686926
Jul 2024818130
Aug 2024585828
Sep 2024535897
Oct 20247071118
Nov 20246061147
Dec 202411311672
Jan 2025767635
Feb 2025676739
Mar 2025747443
Apr 202510210538
May 2025757530
Jun 2025444418
Total526453352529